Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natrecor Safety Labeling Change Likely, J&J Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is in discussions with FDA to “ensure that correct conclusions are in label.” Adverse publicity from Circulation article questioning kidney safety of CHF drug is having an impact; mortality analysis in JAMA will raise more questions.

You may also be interested in...



Natrecor Concerns Are Limiting Use Of Other IV Vasoactive Therapies As Well, JAMA Finds

Decline in use of other congestive heart failure therapies raises concerns about the effect of articles that question the safety of approved medications.

Natrecor Concerns Are Limiting Use Of Other IV Vasoactive Therapies As Well, JAMA Finds

Decline in use of other congestive heart failure therapies raises concerns about the effect of articles that question the safety of approved medications.

Scios Final Analysis Of Natrecor Trial Finds Two Additional Deaths

Johnson & Johnson subsidiary maintains the additional deaths have “no impact on overall risk/benefit profile” of the heart failure therapy.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel